Romijn Geke, Riper Heleen, Kok Robin, Donker Tara, Goorden Maartje, van Roijen Leona Hakkaart, Kooistra Lisa, van Balkom Anton, Koning Jeroen
Faculty of Behavioural and Movement Sciences, Department of Clinical Psychology, VU University Amsterdam, Van der Boechorststraat 1, BT 1081, Amsterdam, The Netherlands.
EMGO Institute for Health Care and Research, VU University Medical Centre, Van der Boechorststraat 7, BT 1081, Amsterdam, The Netherlands.
BMC Psychiatry. 2015 Dec 12;15:311. doi: 10.1186/s12888-015-0697-1.
Anxiety disorders are among the most prevalent psychiatric conditions, and are associated with poor quality of life and substantial economic burden. Cognitive behavioural therapy is an effective treatment to reduce anxiety symptoms, but is also costly and labour intensive. Cost-effectiveness could possibly be improved by delivering cognitive behavioural therapy in a blended format, where face-to-face sessions are partially replaced by online sessions. The aim of this trial is to determine the cost-effectiveness of blended cognitive behavioural therapy for adults with anxiety disorders, i.e. panic disorder, social phobia or generalized anxiety disorder, in specialized mental health care settings compared to face-to-face cognitive behavioural therapy. In this paper, we present the study protocol. It is hypothesized that blended cognitive behavioural therapy for anxiety disorders is clinically as effective as face-to-face cognitive behavioural therapy, but that intervention costs may be reduced. We thus hypothesize that blended cognitive behavioural therapy is more cost-effective than face-to-face cognitive behavioural therapy.
METHODS/DESIGN: In a randomised controlled equivalence trial 156 patients will be included (n = 78 in blended cognitive behavioural therapy, n = 78 in face-to-face cognitive behavioural therapy) based on a power of 0.80, calculated by using a formula to estimate the power of a cost-effectiveness analysis: [Formula: see text]. Measurements will take place at baseline, midway treatment (7 weeks), immediately after treatment (15 weeks) and 12-month follow-up. At baseline a diagnostic interview will be administered. Primary clinical outcomes are changes in anxiety symptom severity as measured with the Beck Anxiety Inventory. An incremental cost-effectiveness ratio will be calculated to obtain the costs per quality-adjusted life years (QALYs) measured by the EQ-5D (5-level version). Health-economic outcomes will be explored from a societal and health care perspective.
This trial will be one of the first to provide information on the cost-effectiveness of blended cognitive behavioural therapy for anxiety disorders in routine specialized mental health care settings, both from a societal and a health care perspective.
Netherlands Trial Register NTR4912. Registered 13 November 2014.
焦虑症是最常见的精神疾病之一,与生活质量差和巨大的经济负担相关。认知行为疗法是减轻焦虑症状的有效治疗方法,但成本高昂且劳动强度大。通过采用混合形式提供认知行为疗法,其中面对面治疗部分被在线治疗取代,可能会提高成本效益。本试验的目的是确定与面对面认知行为疗法相比,在专业心理健康护理环境中,混合认知行为疗法对患有焦虑症(即恐慌症、社交恐惧症或广泛性焦虑症)的成年人的成本效益。在本文中,我们展示了研究方案。假设针对焦虑症的混合认知行为疗法在临床上与面对面认知行为疗法一样有效,但干预成本可能会降低。因此,我们假设混合认知行为疗法比面对面认知行为疗法更具成本效益。
方法/设计:在一项随机对照等效性试验中,将根据使用成本效益分析功效估计公式计算得出的0.80功效纳入156名患者(混合认知行为疗法组n = 78,面对面认知行为疗法组n = 78):[公式:见原文]。测量将在基线、治疗中期(7周)、治疗结束后立即(15周)和12个月随访时进行。在基线时将进行诊断访谈。主要临床结局是用贝克焦虑量表测量的焦虑症状严重程度的变化。将计算增量成本效益比,以获得通过EQ - 5D(5级版本)测量的每质量调整生命年(QALY)的成本。将从社会和医疗保健角度探索健康经济结局。
本试验将是首批从社会和医疗保健角度提供关于在常规专业心理健康护理环境中针对焦虑症的混合认知行为疗法成本效益信息的试验之一。
荷兰试验注册NTR4912。2014年11月13日注册。